Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for prevention of postoperative Crohn's disease recurrence after ileocecal resection
2008-005688-32Phase 3Completed
- Sponsor
- Bulovka University Hospital
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in Crohn's disease comparing Infliximab postoperative prophylaxis with Placebo (2 arms). Primary endpoints: Incidence of endoscopic recurrence at 24 months, Rate of clinical relapse and 3 more. Started Jan 2009; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2008-005688-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005688-32.